1. In silico characterisation of putative Plasmodium falciparum vaccine candidates in African malaria populations
- Author
-
Umberto D'Alessandro, Marielle K. Bouyou-Akotet, Deus S. Ishengoma, Kolapo Oyebola, E Kamau, Lucas Amenga-Etego, M F Diop, Tobias O. Apinjoh, Lemu Golassa, William Yavo, Milijaona Randrianarivelojosia, Oumou Maïga-Ascofaré, Alfred Amambua-Ngwa, Ben Andagalu, Anita Ghansah, Olumide Ajibola, and Abdoulaye Djimde
- Subjects
Science ,Plasmodium falciparum ,Population ,Protozoan Proteins ,Antigens, Protozoan ,Balancing selection ,Article ,Epitope ,Epitopes ,Antigen ,Malaria Vaccines ,parasitic diseases ,medicine ,Sequencing ,Humans ,Computer Simulation ,Prospective Studies ,Malaria, Falciparum ,education ,Genetics ,Vaccines ,education.field_of_study ,Multidisciplinary ,biology ,Malaria vaccine ,Genomics ,biology.organism_classification ,medicine.disease ,Vaccine efficacy ,Antigenic Variation ,Africa ,Infectious diseases ,Medicine ,Malaria - Abstract
Genetic diversity of surface exposed and stage specific Plasmodium falciparum immunogenic proteins pose a major roadblock to developing an effective malaria vaccine with broad and long-lasting immunity. We conducted a prospective genetic analysis of candidate antigens (msp1, ama1, rh5, eba175, glurp, celtos, csp, lsa3, Pfsea, trap, conserved chrom3, hyp9, hyp10, phistb, surfin8.2, and surfin14.1) for malaria vaccine development on 2375 P. falciparum sequences from 16 African countries. We described signatures of balancing selection inferred from positive values of Tajima’s D for all antigens across all populations except for glurp. This could be as a result of immune selection on these antigens as positive Tajima’s D values mapped to regions with putative immune epitopes. A less diverse phistb antigen was characterised with a transmembrane domain, glycophosphatidyl anchors between the N and C- terminals, and surface epitopes that could be targets of immune recognition. This study demonstrates the value of population genetic and immunoinformatic analysis for identifying and characterising new putative vaccine candidates towards improving strain transcending immunity, and vaccine efficacy across all endemic populations.
- Published
- 2021